Infinity Pharmaceuticals | INFI - Net Income


Infinity Pharmaceuticals reported $-9.96M in Net Income for its fiscal quarter ending in June of 2023.





Net Income Change Date
AbbVie USD 695M 1.12B Mar/2026
Alterity Therapeutics Limited AUD -6.3M 525.41K Dec/2025
Amgen USD 1.82B 486M Mar/2026
AstraZeneca USD 3.08B 754M Mar/2026
Bristol-Myers Squibb USD 2.68B 1.59B Mar/2026
Cipla INR 6.76B 6.75B Dec/2025
Clal Biotechnology ILS -6.17M 15.56M Dec/2022
Compugen USD 56.84M 63.82M Dec/2025
CSL USD 401M 96.5M Dec/2025
Eisai JPY 17.18B 7.02B Dec/2025
Eli Lilly USD 7.4B 760M Mar/2026
Gilead Sciences USD 2.02B 162M Mar/2026
GlaxoSmithKline GBP 1.74B 1.1B Mar/2026
Grifols EUR 114.37M 34.03M Dec/2025
Incyte USD 303.33M 4.05M Mar/2026
Infinity Pharmaceuticals USD -9.96M 1.09M Jun/2023
Ionis Pharmaceuticals USD -93M 136M Mar/2026
J&J USD 5.24B 119M Mar/2026
Novartis USD 3.16B 747M Mar/2026
Pfizer USD 2.69B 4.34B Mar/2026
Plus Therapeutics USD -5.71M 1.29M Dec/2025
Roche Holding CHF 5.47B 1.76B Dec/2025
TG Therapeutics USD 19.78M 3.26M Mar/2026